CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of urothelial bladder cancer.
  
  LEARNING OBJECTIVES

  • Consider available data supporting the use of anti-PD-1 antibody therapy for high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into current care.
  • Evaluate the FDA-approved indication for adjuvant anti-PD-1 antibody therapy for patients with high-risk muscle-invasive bladder cancer (MIBC), and consider the current role of this strategy.
  • Recognize how biologic and patient-specific factors influence the selection and sequencing of treatment for metastatic UBC.
  • Review available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed metastatic UBC, and determine the current utility of these agents in clinical practice.
  • Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients for whom these approaches would be appropriate.
  • Appreciate the biologic rationale for combining anti-PD-1/PD-L1 antibodies with other systemic agents with established efficacy in UBC, and assess the current and potential roles of these regimens in patient care.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for advanced or metastatic UBC.
  • Develop an understanding of the biologic rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for NMIBC, MIBC and metastatic UBC.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AUA2023/UBC/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Sia Daneshmand, MD
  Professor of Urology and Medicine (Oncology) — Clinical Scholar
  Director of Urologic Oncology
  Director of Clinical Research
  Urologic Oncology Fellowship Director
  USC/Norris Comprehensive Cancer Center
  Los Angeles, California
  
  Consulting Agreements: Bristol Myers Squibb, CG Oncology, Ferring Pharmaceuticals, Janssen Biotech Inc, Pacific Edge, Pfizer Inc, Photocure, Protara Therapeutics, QED Therapeutics; Contracted Research: Janssen Biotech Inc, Pacific Edge, Photocure, Protara Therapeutics; Stock Options/Ownership — Public Company: TARIS Biomedical LLC (Johnson & Johnson Pharmaceuticals); Nonrelevant Financial Relationship: Catalyst Clinical Research.
  
  Joshua J Meeks, MD, PhD
  Associate Professor of Urology, Biochemistry and Molecular Genetics
  Northwestern University Feinberg School of Medicine
  Chicago, Illinois
  
  Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Imvax Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Prokarium, Seagen Inc, UroGen Pharma; Consulting Agreement: Janssen Biotech Inc; Contracted Research: Epizyme Inc, Merck; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, STEBA Biotech NV.
  
  Matthew Milowsky, MD
  George Gabriel and Frances Gable Villere Distinguished Professor
  Vice Chief for Research and Education
  Section Chief, Genitourinary Oncology
  UNC Division of Oncology
  Co-Lead, Clinical and Translational Research
  Co-Director, Urologic Oncology Program
  UNC Lineberger Comprehensive Cancer Center
  Chapel Hill, North Carolina
  
  Advisory Committee and Consulting Agreement: Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: ALX Oncology, Arvinas, Bristol Myers Squibb, Clovis Oncology, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mirati Therapeutics Inc, Seagen Inc; Stock Options/Ownership — Public Company: Gilead Sciences Inc, Merck, Pfizer Inc; Nonrelevant Financial Relationship: Alliance for Clinical Trials in Oncology, Alliance Foundation Trials LLC, Elsevier (Co-Editor-in-Chief, Clinical Genitourinary Cancer), Hoosier Cancer Research Network Inc, Medscape (educational videos).
  
  J Alfred Witjes, MD, PhD
  Professor
  Chair of Oncological Urology
  Radboud University Medical Centre
  Nijmegen, The Netherlands
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR
  Arlene Siefker-Radtke, MD
  Professor
  Department of Genitourinary Medical Oncology
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bristol Myers Squibb, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IDEAYA Biosciences, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mirati Therapeutics Inc, Nektar, Seagen Inc, Taiho Oncology Inc; Contracted Research: Basilea Pharmaceutica Ltd, Bristol Myers Squibb, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, Nektar, Takeda Pharmaceuticals USA Inc; Honoraria: Janssen Biotech Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas and Seagen Inc, Bristol Myers Squibb, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.
  
  Release date: May 2023
  Expiration date: May 2024
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.